Ypsomed Holding AG · SIX:YPSN
Ypsomed — HY 2026/27 Earnings Presentation
40 slides from Ypsomed's earnings presentation, Nov 11, 2026
Slide 1: Ypsomed Half Year Results 2026/27
Ypsomed Half Year Results 2026/27 Transforming selfcare, transforming Ypsomed Webcast, 11 November 2026
Slide 2: Important information
Important information The information contained in this document has not been verified by an independent source. It should be taken with caution, and no assurance or guarantee is given (either explicit or implied) regarding the fairness, accuracy, completeness or correctness of the information or op
Slide 3: Making selfcare simpler and easier
Making selfcare simpler and easier 3 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 4: Ypsomed benefits from multiple structural growth drivers
Ypsomed benefits from multiple structural growth drivers Selfcare – treatment moving home, from IV to subcutaneous delivery to enhance quality of life and lower healthcare cost Biologics – most next-generation therapies are large molecules that must be injected Biosimilars – affordable medicines inc
Slide 5: Ypsomed has completed its transformation to a pure-play self-injection specialist
Ypsomed has completed its transformational journey to become a pure-play self-injection specialist Ypsomed: pure play self-injection specialist 2026 Phase-out of contract manufacturing Delivery Systems 2025 Sale of Ypsotec 2025 Sale of Diabetes Care 2024 Sale of pen needle and blood glucose monitori
Slide 6: Full focus on high-growth injectables, sustained growth ahead
Full focus on high-growth injectables, sustained growth ahead Operational Strong Platforms Innovation Excellence Financials 6 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 7: Broadest self-injection offering on the market
Broadest self-injection offering on the market Operational Strong Platforms Innovation Excellence Financials 7 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 8: Ypsomed offers the broadest range of self-injection solutions
Ypsomed offers the broadest range of self-injection solutions on the market 8 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 9: Record 30 new projects won in HY 2026/27
Ypsomed won a record number of 30 new projects in HY 2026/27, thereof 10 with new customers New project wins HY 2026/27 Ypsomed wins across the board Various therapeutic areas Majority for autoimmune 30 new Developed and emerging markets project New and existing pharma customers wins Renew
Slide 10: YpsoMate in >80% of autoinjector regulatory approvals
Outstanding participation rate – YpsoMate in >80 % of autoinjector regulatory approvals in developed markets over the past 12 months Outstanding participation rate >80 %1 of drugs approved by pharma companies in developed markets in last 12 months use YpsoMate Illustrates strength of Ypsomed pip
Slide 11: Wide array of therapeutic areas, clients and modalities
We serve a wide array of therapeutic areas, clients and modalities: >280 clinical and commercial programs for over 130 clients No. accounts No. clinical No. commercial Diabetes/ Insulin Oncology therapies Neurology incretins Diabetes/ Hormone Obesity/ diseases Cardio- vascular Infectious Autoimmune
Slide 12: Over 90 approved products
Ypsomed supports patients with over 90 approved products in 27 indications Pens Autoinjectors Psoriasis Diabetes Asthma Rheumatoid Arthritis Alzheimer Sexual dysfunction Fertility Atopic Dermatitis Hereditary Angioedema >90 Growth Disorders ATTR Amyloidosis Fam. Chylomicronem
Slide 13: Diversified customer portfolio, no customer above 15% of revenue
Ypsomed has a diversified customer portfolio with no customer exceeding 15 % of revenue in the foreseeable future Commercial sales by customer HY 2026/27 Increasingly diversified portfolio Illustrative More than 130 customers No single customer accounts for more than 15 % of commercial revenue O
Slide 14: Ypsomed is the innovation leader
Ypsomed is the innovation leader Operational Strong Platforms Innovation Excellence Financials 14 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 15: CPHI Milan – Connecting with global pharma and biotech partners
CPHI Milan – Connecting with global pharma and biotech partners - 15 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 16: PDA Palm Springs – strengthening partnerships in drug delivery
PDA Palm Springs – strengthening partnerships in drug delivery 16 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 17: YpsoMate clear-to-clinic offering in clinical studies
The YpsoMate clear-to-clinic offering in clinical studies can reduce cost and risks, while shortening time to market STEP 1 STEP 2 STEP 3 RESULT Implement Autoinjector usage Skip pharmaco- Faster timeline, autoinjector in allows to conduct kinetic bridging reduced risk, cost Phase II clinical large
Slide 18: Five new projects won with Clear-to-Clinic offering
Innovation already translates into new deals: Five new projects won with the new Clear-to-Clinic offering Clinic-ready devices in few months Innovative offering consisting of a complete service package: − Documentation − Verification − Parallelization − Early readiness Cost reduction, de-risked
Slide 19: Advancing Business and Artificial Intelligence with Intelligence Center
We are advancing Business and Artificial Intelligence with our Intelligence Center 19 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 20: Ypsomed expands with a flexible setup to meet growing demand
Ypsomed expands with a flexible setup to meet growing demand Operational Strong Platforms Innovation Excellence Financials 20 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 21: Global manufacturing footprint, local for local
Ypsomed builds a global manufacturing footprint, producing local for local Holly Springs (USA) Schwerin (DE) Schwerin II (DE) opening 2027 opening 2027 Burgdorf HQ (CH) Solothurn (CH) Burgdorf (CH) Burgdorf (CH) Changzhou (CN) 21 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 22: Solothurn: phasing out contract manufacturing frees space for automation
In Solothurn, phasing out contract manufacturing frees space for state-of-the-art automation 22 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 23: Changzhou, commercial production started end of 2025
In Changzhou, commercial production has started end of 2025 23 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 24: Changzhou, commercial production started end of 2025
In Changzhou, commercial production has started end of 2025 24 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 25: Schwerin extension on track to open mid-2027
In Schwerin, extension is on track to open in mid-2027 25 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 26: Holly Springs new site on track to open end of 2027
In Holly Springs (NC, USA), our new site is on track to open end of 2027 26 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 27: Holly Springs interior construction on track
In Holly Springs (NC, USA), interior construction is on track 27 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 28: Ypsomed continues to deliver strong financial results
Ypsomed continues to deliver strong financial results Operational Strong Platforms Innovation Excellence Financials 28 | Ypsomed Holding AG | Half year results 2026/27 PUBLIC
Slide 29: Reported revenue of CHF 318 million in HY 2026/27
Reported revenue of CHF 318 million in HY 2026/27 Sales by segment Delivery Systems driving growth HY 2026/27 in CHF million Diabetes Care fully divested in FY 31 2025/26 and no longer generating any revenues Others includes legacy businesses, 318 mainly contract manufacturing (“CM”) for pens
Slide 30: Delivery Systems grows around 17.5% in the first half year
Delivery Systems grows around 17.5 % in the first half year Delivery Systems sales Sustained growth trajectory HY 2026/27 548. 5 243 44 287 Strong commercial sales growth driven by autoinjectors, especially YpsoMate 201 43 244 1.0 mL and 2.25 mL Capacity reservation fees shown within in million
Slide 31: Delivery Systems operating income and 35.7% EBIT margin
Delivery Systems operating income reached around CHF 102 million EBIT by segment Delivery Systems delivers 35.7 % EBIT HY 2026/27 margin Delivery Systems strong profitability despite ramp up and volume-based 102 -3 100 pricing in million CHF Others includes divestment one-offs for Diabetes Care,
Slide 32: Focus on growth investments
Focus on growth investments Reported cash flow Cash flow HY 2026/27 Delivery Systems drives strong operational cash flow 117 -125 Investing cash flow reflects significant capacity expansion (growth capex) in million CHF investments -8 9 Fin. CF 17 CF Op. CF FCF Total CF Invest. 32 | Ypsomed Hold
Slide 33: Continued investments in infrastructure and R&D
Continued investments in infrastructure and R&D lay the foundation for future growth Asset investments Fixed assets expansion HY 2026/27 YpsoMate and UnoPen 126 20 146 130 14 144 Across Switzerland, Germany, the US, and China in million CHF Intangible assets: R&D investment Intangible assets N
Slide 34: Capex program of CHF 1.3 billion on track, peaking in 2026/27
Capex program of CHF 1.3 billion on track, reaching a peak in 2026/27 Growth capex program Flexible and modular manufacturing Illustrative, total fixed assets investments 20% ROCE for Delivery Systems amidst expansion Approved investment includes customer contribution in million CHF Capex st
Slide 35: Solid balance sheet fully funds organic growth
Ypsomed’s strong fundamentals and solid balance sheet fully fund our organic growth CHF 300 million net debt as of 30 September 2026 CHF 308 million EBITDA Delivery Systems in last 12 months ~1.0x net debt / EBITDA for Delivery Systems Ypsomed's strong balance sheet enables to execute growth strateg
Slide 36: Ypsomed raises guidance for FY 2026/27
Ypsomed raises guidance for the FY 2026/27 Delivery Systems Sales 601 Increased Guidance: Sales growth: 13–16 % (previously: 12−15 %) EBIT CHF 220−240 million (previously: 210−230) in million CHF 559 EBIT margin >33 % 2025/26 2026/27 Note: Guidance is provided for Delivery Systems, excluding Contrac
Slide 37: Well-positioned for robust growth until the end of the decade
Ypsomed is well-positioned to deliver robust growth until the end of the decade and beyond Net Sales Mid-term ambition (FY 2029/30) Illustrative CHF 0.9−1.1 billion sales (midpoint 15 % CAGR) CHF 280−340 million EBIT (not less than 30% EBIT margin) Stable ROCE (~20%) (all years) Strong susta
Slide 38: We look forward to your questions.
We look forward to your questions.
Slide 39: Ypsomed raises outlook for the FY 2026/27
Ypsomed raises outlook for the FY 2026/27 Prior Delivery Systems Guidance New Delivery Systems Guidance Low Mid High Low Mid High Sales 625 635 645 Sales 630 640 650 in million CHF in million CHF Sales * Sales * growth 12 % 13.5% 15 % growth 13 % 14.5% 16 % EBIT 210 220 230 EBIT 220 230 240 EBIT >33
Slide 40: HY 2026/27 highlights
HY 2026/27 highlights Ypsomed delivers 17.5 % Delivery Systems growth and a 35.7 % EBIT margin Delivery Systems sales of CHF 286.6 million, up 17.5 %. Commercial sales grew 20.6% Delivery Systems LTM sales around CHF 602 million, EBITDA of CHF 308 million Delivery Systems EBIT of CHF 102.3 m